Live
FierceBiotechWave crashes after obesity trial tracks 1% dip in body weight over 6 monthsFierceBiotechPulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapsesFierceBiotechOrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipelineFierceBiotechPhilips AI cath lab copilot nets FDA clearanceThermo FisherIs Thermo Fisher Scientific (TMO) One of the Best Conservative Stocks to Buy Right Now? - Yahoo FinanceBioPharma DiveFDA clears Denali drug in ‘clear step’ for rare disease biotechsEndpoints NewsWave crashes on obesity disappointmentLonza NewsBRIEF—Lonza launches new development lab in Singapore - The Pharma LetterBioPharma DiveWave crashes on obesity drug update; Kodiak’s reboot pays dividendsEndpoints NewsKodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 programEndpoints NewsLimbic aims to show AI beats humans in delivering therapyEndpoints NewsPost-Hoc: It’s time to make ACIP serious again
Endpoints News Mar 26, 2026

Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program

Original
Body unavailable. Use the original source.

Directory

59 All